EGFR and cholangiocarcinoma: Lapatinib. Lapatinib, a dual inhibitor of EGFR and ERBB2, markedly reduced 80–95% of the growth of CC cells by EGFR/ERBB2 and its downstream signaling pathways, including the AKT and MAPK signaling pathways.